Royal Sense Ltd Declares Unaudited September Half-Year Results
Key highlights
- Royal Sense Ltd declared unaudited financial results for the half-year ended September 30, 2026.
- The supplied disclosure does not state revenue, profit, margin or earnings-per-share figures for the half-year.
- TTG Innovations reported turnover of ₹15.72 crore as of March 2025 and is proposed to merge with Royal Sense.
- Royal Sense disclosed the release of 10 lakh pledged promoter shares, representing an 18.7% stake.
powered by IRIS

Royal Sense Ltd declared unaudited financial results for the half-year ended September 30, 2026, through its board-meeting outcome, although the supplied disclosure does not provide revenue, profit, margin, or earnings-per-share figures.
Know Royal Sense inside out
Results, valuation, peers and who's buying, in one view.
What did Royal Sense Ltd's board declare for September 2026?
Royal Sense Ltd's board declared unaudited financial results for the six months ended September 30, 2026. The announcement is identified as a board-meeting outcome under the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements framework.
The available material confirms the period covered by the results but does not reproduce the financial statements or their key line items. As a result, the disclosure provided does not allow investors to calculate half-year revenue growth, profitability, operating margins, net profit, cash generation, or any comparison with an earlier period.
Royal Sense is a listed public limited company incorporated on April 6, 2023, with its registered office in Delhi. It operates in the healthcare trading segment, supplying medical devices, pharmaceuticals, diagnostics, surgical products, laboratory products and disposable medical supplies to hospitals, laboratories, clinics and institutions.
What financial information is available in the supplied results disclosure?
The supplied results disclosure confirms the declaration of unaudited half-year results but does not include the underlying financial figures. No information is stated on sales, other income, expenses, profit before tax, profit after tax, earnings per share, borrowings, working capital, inventory, receivables, or cash flows.
This distinction matters because a board-meeting outcome is not, by itself, sufficient to assess financial performance when the detailed result tables are unavailable. Retail investors would need the complete exchange filing and accompanying unaudited financial statements to review the company’s reported numbers and auditor-related disclosures, if any.
The material also does not state how the September 2026 half-year performance compares with the corresponding six months of the previous year. Therefore, no conclusion can be drawn from the provided information about whether Royal Sense’s revenue, profit or margins increased or declined during the period.
How does Royal Sense Ltd operate in the healthcare supply market?
Royal Sense operates as a healthcare trading house rather than as a manufacturer. The company supplies surgical accessories, instruments, equipment, consumables, reagents, diagnostic kits, branded drugs and mobility aids, among other medical products.
Its business model serves hospitals, clinics, laboratories and institutions that require a range of healthcare products. The company information describes a broad catalogue intended to support procurement requirements across surgical, diagnostic and pharmaceutical categories.
The company was formed in 2023 from the merger of three family-run medical-supply businesses whose operating roots extend to 2015, according to the supplied company profile. Its relatively recent listed-company history makes periodic financial disclosures important for tracking the development of the combined business.
Royal Sense has one wholly owned operating subsidiary, Stergic Retail Private Limited. Stergic Retail runs the Stergic Pharmacy network and is described as both a customer of Royal Sense and a recipient of inter-corporate advances, making related-party disclosures relevant to an assessment of group transactions.
Got a follow-up? Ask IRIS
What is the status of the TTG Innovations merger?
Royal Sense is pursuing the merger by absorption of TTG Innovations Private Limited, a related party involved in pharmaceuticals and healthcare products. The proposed scheme provides for the issue of 18.1 Royal Sense shares for every one TTG share.
The Royal Sense board approved the merger scheme on May 26, 2025, under Sections 230 to 232 of the Companies Act, 2013. BSE Limited issued a no-adverse observation letter dated November 19, 2025, allowing the company to proceed with filing the scheme before the National Company Law Tribunal, subject to 15 conditions.
TTG reported turnover of ₹15.72 crore as of March 2025, based on the ₹1,572.45 lakh figure in the supplied material. TTG was also awarded a tender by the Central Procurement Agency under the Directorate General of Health Services for various types of sutures, including absorbable, non-absorbable, monofilament, braided and specialty products.
The merger remains a material corporate development because it involves a related party in which a director has an interest. The supplied material describes continuing restructuring activity but does not state that the scheme has received final NCLT approval or been completed.
How could the disclosure affect Royal Sense Ltd investors and operations?
The half-year result declaration is relevant to investors because it covers the company’s latest disclosed reporting period, but the supplied text does not include figures that would show the immediate financial impact. Investors cannot use this announcement alone to assess valuation, earnings momentum or the balance-sheet position.
Royal Sense’s operations are connected to healthcare procurement demand across hospitals, clinics, laboratories and institutional buyers. Its product range spans medical equipment, surgical instruments, consumables, laboratory equipment, reagents, disposables and diagnostic kits, so operating performance may depend on product availability, customer orders, tender activity and working-capital management. The supplied result notice does not quantify these factors.
The company also disclosed that promoter Rishabh Arora clarified the release of 10 lakh pledged shares, representing an 18.7% stake. Separately, shareholders approved a ₹10 crore capital increase, an employee stock option scheme and the reappointment of the managing director at the annual general meeting reported on September 5, 2026.
These corporate actions provide context for shareholders monitoring ownership, capital structure and the pending TTG transaction. However, the available information does not establish a direct financial effect from any of these actions on the September 2026 half-year results.
Conclusion
Royal Sense Ltd has formally declared unaudited financial results for the half-year ended September 30, 2026, but the supplied board-meeting outcome does not disclose the financial statements or key performance numbers. The company remains a healthcare products trader with a wholly owned pharmacy-network subsidiary and an ongoing related-party merger proposal involving TTG Innovations.
The next items to watch are the detailed unaudited financial results, including revenue, profit and balance-sheet data, and progress in the TTG merger process after the BSE observation letter. Investors may also track disclosures relating to the approved ₹10 crore capital increase, the ESOP scheme and promoter shareholding changes.


